Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reveal 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix

Trial Profile

Reveal 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs VGX 3100 (Primary)
  • Indications Cervical dysplasia; Cervical intraepithelial neoplasia; Human polyomavirus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms REVEAL 2
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 08 Nov 2018 According to an Inovio Pharmaceuticals media release, this trial is expected to begin in early 2019 and interim efficacy data is expected in 2019.
    • 06 Jul 2017 New trial record
    • 08 Jun 2017 According to an Inovio Pharmaceuticals media release, both REVEAL 1 and REVEAL 2 studies will be conducted in parallel. Mark Einstein is Principal Investigator for the studies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top